Provided are a
fluorine-containing
amino acid prodrug represented by general formula (I) that makes a
fluorine-containing
amino acid which is a group 2
metabotropic glutamate receptor agonist into a
prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a
prodrug that increases the
in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as:
schizophrenia,
anxiety disorder and its related diseases, depression, bipolar disorder,
epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and
drug dependence, cognitive disorders, Alzheimer's
disease, Huntington's
chorea, Parkinson's
disease,
movement disorders associated with muscular rigidity, cerebral
ischemia, cerebral insufficiency,
spinal cord disorders, cephalopathy, and other neurological diseases.